Promising Results in Immunity Pharma’s Interim Phase 1/2a IPL344 in ALS Study
The new treatment being developed by Immunity Pharma may give ALS (Lou Gehrig’s Disease) patients hope. ALS is an “orphan disease” – one that affects few people. In the U.S.,…
Continue Reading
Promising Results in Immunity Pharma’s Interim Phase 1/2a IPL344 in ALS Study